Resource Summary Report

Generated by NIF on Apr 9, 2025

Cancer Research UK

RRID:SCR_004041
Type: Tool

Proper Citation

Cancer Research UK (RRID:SCR_004041)

Resource Information

URL: http://www.cancerresearchuk.org/

Proper Citation: Cancer Research UK (RRID:SCR_004041)

Description: Cancer Research UK is the world''s leading charity dedicated to beating cancer through research. We''ve saved millions of lives with our groundbreaking work into preventing, diagnosing and treating cancer. People''s chances of surviving cancer have doubled in the last 40 years, and we''ve been at the heart of that progress. But more than one in three of us will still get cancer at some point. Our vital work, funded entirely by the public, will help ensure that millions more people survive. Our aim is to save lives from cancer. More people are beating cancer than ever before thanks to our work and your support. We work in the areas where we can make the most impact: * Research we support the work of over 4,000 scientists, doctors and nurses across the UK to investigate all aspects of cancer. * Information we work to prevent cancer and help people cope with its effects by providing information for cancer patients and their families, health professionals and the general public. * Influencing public policy we campaign to keep cancer at the top of the health agenda. Cancer Research UK is a registered charity in England and Wales (1089464) and in Scotland (SC041666). Registered as a company limited by guarantee in England & Wales No. 4325234.

Abbreviations: CRUK

Resource Type: institution

Funding:

Resource Name: Cancer Research UK

Resource ID: SCR_004041

Alternate IDs: Wikidata: Q326079, Crossref funder ID: 501100000289, nlx_143542, grid.11485.39, ISNI: 0000 0004 0422 0975

Alternate URLs: https://ror.org/054225q67

Record Creation Time: 20220129T080222+0000

Record Last Update: 20250214T183008+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Research UK.

No alerts have been found for Cancer Research UK.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 374 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Erickson A, et al. (2025) Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers. PloS one, 20(1), e0316475.

Carr M, et al. (2024) Testing a faith-placed education intervention for bowel cancer screening in Muslim communities using a two-group non-randomised mixed-methods approach: Feasibility study protocol. PloS one, 19(3), e0293339.

Lei J, et al. (2024) Human papillomavirus genotype and cycle threshold value from self-samples and risk of high-grade cervical lesions: A post hoc analysis of a modified stepped-wedge implementation feasibility trial. PLoS medicine, 21(12), e1004494.

Bingham V, et al. (2024) Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications. Scientific reports, 14(1), 11361.

Ney A, et al. (2024) Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection. PLoS computational biology, 20(8), e1012408.

Hamilton-West KE, et al. (2024) Development of an implementation science informed "Test Evidence Transition" program to improve cancer outcomes. Frontiers in health services, 4, 1328342.

Gadsby JR, et al. (2024) The open to closed D-loop conformational switch determines length in filopodia-like actin bundles. The Biochemical journal, 481(24), 1977.

Yarmolinsky J, et al. (2024) Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis. EBioMedicine, 100, 104991.

Bernacchia L, et al. (2023) Developing novel antimicrobials by combining cancer chemotherapeutics with bacterial DNA repair inhibitors. PLoS pathogens, 19(12), e1011875.

Farncombe KM, et al. (2023) Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy. American journal of human genetics, 110(10), 1616.

Barrott L, et al. (2023) Nurse and pharmacist systemic anti-cancer therapy review clinics and their impact on patient experience and care: A systematic review. Journal of advanced nursing, 79(2), 442.

Tarantola A, et al. (2023) Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. Journal of pharmaceutical policy and practice, 16(1), 67.

Berman AG, et al. (2023) SliDL: A toolbox for processing whole-slide images in deep learning. PloS one, 18(8), e0289499.

Puppo M, et al. (2023) MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness. British journal of cancer, 129(5), 754.

Hamilton FW, et al. (2023) Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study. PLoS medicine, 20(1), e1004174.

Brigden T, et al. (2023) Ethical and legal implications of implementing risk algorithms for early detection and screening for oesophageal cancer, now and in the future. PloS one, 18(10), e0293576.

Yarmolinsky J, et al. (2023) Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis. Diabetologia, 66(8), 1481.

Burda PC, et al. (2023) Global analysis of putative phospholipases in Plasmodium falciparum reveals an essential role of the phosphoinositide-specific phospholipase C in parasite maturation. mBio, 14(4), e0141323.

Raat EM, et al. (2023) Early signs of cancer present in the fine detail of mammograms. PloS one, 18(4), e0282872.

Vera-Siguenza E, et al. (2023) Mathematical reconstruction of the metabolic network in an in-vitro multiple myeloma model. PLoS computational biology, 19(9), e1011374.